Ambroxol chaperones GCase; in a previous study of people with Parkinson's disease, the drug led to increased GCase levels. It ...

A 12-month study found that Ambroxol helped stabilised psychiatric symptoms and protected against brain damage in genetically ...

Researchers at Lawson Research Institute (Lawson), the research arm of St. Joseph's Health Care London, are investigating ...

A clinical trial has revealed that Ambroxol, a common cough medicine in Europe, may help slow cognitive decline in people with Parkinson’s disease dementia.

Dementia poses a major health challenge with no safe, affordable treatments to slow its progression. Researchers at Lawson ...

A commonly sold cough syrup in Europe could potentially slow down progression of dementia in patients with Parkinson’s ...

A cough medicine used for decades in Europe called Ambroxol has shown promise for treating dementia in people with ...

Ambroxol supports a key enzyme called glucocerebrosidase (GCase), which is produced by the GBA1 gene. In people with Parkinson's disease, GCase levels are often low.

Ambroxol supports a key enzyme called glucocerebrosidase (GCase), which is produced by the GBA1 gene. In people with Parkinson’s disease, GCase levels are often low.

Ambroxol boosts levels of an enzyme called GCase, which is known to help clear away waste products which have gathered in brain cells. In Parkinson’s, a build up of a troublesome protein called ...

“Ambroxol was safe, well-tolerated, and demonstrated target engagement,” scientists wrote, however adding that the drug’s clinical effect on cognition was “not confirmed” in the study.